Table 2 Comparison of clinical characteristics and OCT findings between the CSC responders and CSC non-responders
|  | CSC Responders (n = 17, 40.5%) | CSC non-responders (n = 25, 59.5%) | p-value |
|---|---|---|---|
Clinical characteristics | |||
 Sex (male: female) | 14: 3 | 20: 5 |  |
 Age (years) | 51.1 ± 7.5 | 50.5 ± 9.4 | 0.965†|
 Hypertension (yes: no) | 4: 13 | 3: 22 | 0.325* |
 Diabetes (yes: no) | 0: 17 | 0: 25 | 1.000* |
 Visual acuity (LogMAR) | 0.251 ± 0.317 | 0.211 ± 0.269 | 0.662†|
 Duration of symptom (wk) | 10.5 ± 4.8 | 8.6 ± 3.9 | 0.162†|
 First event: Recurrence | 14: 3 | 21:4 | 0.888* |
Baseline OCT findings | |||
 Baseline CRT (µm) | 424.65 ± 129.56 | 458.52 ± 122.41 | 0.395†|
 Baseline SFChT (µm) | 379.86 ± 118.08 | 366.82 ± 96.58 | 0.697†|
 Baseline SRF height (µm) | 256.25 ± 164.81 | 225.94 ± 126.07 | 0.504†|
 Baseline PED height (µm) | 63.18 ± 38.18 | 61.51 ± 96.04 | 0.938†|
Changes of OCT findings at 1Â month after bevacizumab | |||
 Δ CRT (µm) | − 198.73 ± 122.32 | − 88.00 ± 125.43 | 0.010†|
 Δ SFChT (µm) | − 63.92 ± 51.81 | − 23.00 ± 33.24 | 0.005†|
 Δ SRF height (µm) | − 259.73 ± 138.00 | − 67.18 ± 121.72 |  < 0.001†|
 Δ PED height (µm) | − 28.94 ± 41.48 | − 11.69 ± 30.88 | 0.146†|